Analysis of the Association of Matrix Metalloproteinase-1 Gene Promoter (rs1799750) Polymorphism and Risk of Ovarian Cancer. Issue 6 (July 2015)

• Record Type: Journal Article
• Authors: Wang, Lijie; Kong, Beihua
• Is Part Of: International journal of gynecological cancer. Volume 25:Issue 6(2015:Jul.)
• Publication Date: 2015-07
• Subjects: Ovarian cancer -- Matrix metalloproteinase-1 -- Gene polymorphism -- Meta-analysis; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1097/IGC.0000000000000463
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objective: Studies investigating the association between matrix metalloproteinase-1 ( MMP1 ) gene promoter 1607–base pair (bp) polymorphism and ovarian cancer risk have yielded conflicting results. Methods: We therefore carried out a meta-analysis of 754 ovarian cancer cases and 1184 controls from 5 published case-control studies. The strength of the association between MMP1 1607-bp polymorphism and ovarian cancer susceptibility was calculated using pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Results: The results suggest that no statistically significant associations exist between MMP1 1607-bp polymorphisms and ovarian cancer risk in all 4 genetic models (2G2G vs 1G1G: OR, 1.08; 95% CI, 0.81–1.43; P = 0.23; 1G2G vs 1G1G: OR, 1.06; 95% CI, 0.82–1.36; P = 0.15; 1G2G + 2G2G vs 1G1G: OR, 1.05; 95% CI, 0.83–1.34; P = 0.16; 2G2G vs 1G1G + 1G2G: OR, 0.98; 95% CI, 0.80–1.20; P = 0.84). Conclusions: In summary, this meta-analysis showed that the MMP1 1607-bp polymorphism is not associated with ovarian cancer risk.